Skip to main content
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRKR ISIN · US57055L1070 US Manufacturing
Open in API
Filings indexed 899 across all filing types
Latest filing 2017-12-29 Regulatory Filings
Country US United States of America
Listing US MRKR

About Marker Therapeutics, Inc.

https://markertherapeutics.com/

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology is its Multi-Antigen Recognizing (MAR) T cell platform, which utilizes natural, non-genetically modified T cells to recognize and kill heterogeneous tumors. This approach is designed to provide durable anti-tumor responses with a favorable safety profile. Its lead product candidate, MT-601, recognizes six tumor-specific antigens and is being evaluated in a Phase 1 study for patients with lymphoma who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy. The technology was originally developed at Baylor College of Medicine.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3/A. It references securities regulations and the filing process but does not contain financial data, report content, or detailed disclosures. The document is short (2119 characters) and serves as a procedural communication rather than a financial report or announcement of results. It is not an Annual Report, Earnings Release, or any detailed financial filing. It is also not a report publication announcement since it does not mention a report being attached or published. The content fits best under Regulatory Filings (RNS) as a general regulatory communication related to securities registration and compliance.
2017-12-29 English
S-3/A
Regulatory Filings Classification · 100% confidence The document is a Form S-3/A, which is a registration statement filed with the SEC under the Securities Act of 1933. It is a pre-effective amendment to a registration statement, primarily focused on updating exhibits such as auditor's consent and amendments to exhibits. The content includes detailed lists of exhibits and agreements related to securities offerings, warrants, and stock purchase agreements. There is no indication of financial statements, earnings data, management discussion, or other report types. The document is a regulatory filing related to securities registration and amendments, not a financial report or announcement of voting results, management changes, or other categories. Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-12-28 English
Regulatory Filings 2017
Regulatory Filings
2017-12-22 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a letter from TapImmune Inc.'s counsel responding to a comment letter from the SEC's Division of Corporation Finance regarding the company's Form 10-Q for the period ended June 30, 2017. The letter includes an expanded legal opinion from foreign counsel about the statute of limitations on certain payment obligations under a license agreement. The document references the Form 10-K filed March 14, 2017, and the Form 10-Q for June 30, 2017, but it does not contain actual financial statements or substantive financial data itself. Instead, it is a regulatory correspondence addressing SEC staff comments and providing legal opinions related to disclosures in prior filings. The document length is 12,649 characters, which is substantial, but the content is primarily a response letter and legal opinion, not a financial report. According to the rules, such correspondence and legal opinions responding to SEC comments should be classified as Regulatory Filings (RNS), as it does not constitute the actual 10-Q or 10-K report but is a regulatory filing related to those reports.
2017-12-04 English
Regulatory Filings 2017
Regulatory Filings
2017-12-01 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a letter from TapImmune Inc.'s legal counsel responding to a comment letter from the SEC Division of Corporation Finance regarding the company's Form 10-Q for the period ended June 30, 2017. It discusses legal opinions related to derecognition of liabilities and references the Form 10-K filed earlier. The content is primarily a regulatory correspondence addressing SEC comments and providing supplemental legal opinions, not the actual financial report or audit report itself. The document length is 6388 characters, which is relatively short and focused on regulatory communication rather than full financial disclosures. Therefore, this document fits best under Regulatory Filings (RNS) as it is a response to SEC comments and includes legal opinions rather than the actual 10-Q or 10-K report.
2017-11-16 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.